Adaprev (an injectable solution of Mannose 6 Phosphate). The safety trial completed in H2 2011 reported that while safety was similar between the Adaprev and Standard care groups, the preliminary performance results have led the Board to decide to cease further development of Adaprev.
Printer-friendly version